File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy

TitleQuantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy
Authors
Issue Date2007
PublisherBlackwell Publishing Ltd.
Citation
Journal Of Viral Hepatitis, 2007, v. 14 n. 1, p. 55-63 How to Cite?
AbstractAttempts to investigate changes in various forms of intrahepatic hepatitis B virus (HBV) DNA during antiviral therapy have been hampered by limitations in technologies and scarcity of adequate tissue for analysis. We used a sensitive, specific assay to detect and quantitate covalently closed circular DNA (cccDNA) from total intrahepatic HBV DNA in clinical liver specimens. Total HBV DNA and cccDNA from 21 needle-biopsy specimens were quantified, with levels ranging from 0.1 to 9.8 copies/cell and 0.3 to 491.0 copies/cell, respectively. Then, we performed the same determinations on baseline and week-52 liver needle-biopsy specimens from eight patients enrolled in a clinical trial and evaluated the association between intrahepatic HBV DNA levels and serological and virological endpoints. In most patients, levels of intrahepatic HBV DNA, including cccDNA, decreased over the 52-week study, regardless of therapy or serological outcome. Higher ratios of cccDNA to total HBV DNA were detected at week 52 than at baseline indicating a shift in predominance of nonreplicating virus in posttreatment specimens. In patients who achieved treatment-related or spontaneous hepatitis B e antigen (HBeAg) responses, including those harbouring tyrosine-methionine-aspartate-aspartate-mutant HBV, levels of intrahepatic and serum HBV DNA suppression were greater than those in patients without HBeAg responses. In conclusion, this pilot study of intrahepatic HBV replicative forms in patients with chronic hepatitis B indicated that total intrahepatic and, specifically, cccDNA levels are not static but change as a reflection of serological and virological events. © 2007 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/78602
ISSN
2015 Impact Factor: 4.179
2015 SCImago Journal Rankings: 1.815
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBourne, EJen_HK
dc.contributor.authorDienstag, JLen_HK
dc.contributor.authorLopez, VAen_HK
dc.contributor.authorSander, TJen_HK
dc.contributor.authorLonglet, JMen_HK
dc.contributor.authorHall, JGen_HK
dc.contributor.authorKwiatkowski, RWen_HK
dc.contributor.authorWright, Ten_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorCondreay, LDen_HK
dc.date.accessioned2010-09-06T07:44:42Z-
dc.date.available2010-09-06T07:44:42Z-
dc.date.issued2007en_HK
dc.identifier.citationJournal Of Viral Hepatitis, 2007, v. 14 n. 1, p. 55-63en_HK
dc.identifier.issn1352-0504en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78602-
dc.description.abstractAttempts to investigate changes in various forms of intrahepatic hepatitis B virus (HBV) DNA during antiviral therapy have been hampered by limitations in technologies and scarcity of adequate tissue for analysis. We used a sensitive, specific assay to detect and quantitate covalently closed circular DNA (cccDNA) from total intrahepatic HBV DNA in clinical liver specimens. Total HBV DNA and cccDNA from 21 needle-biopsy specimens were quantified, with levels ranging from 0.1 to 9.8 copies/cell and 0.3 to 491.0 copies/cell, respectively. Then, we performed the same determinations on baseline and week-52 liver needle-biopsy specimens from eight patients enrolled in a clinical trial and evaluated the association between intrahepatic HBV DNA levels and serological and virological endpoints. In most patients, levels of intrahepatic HBV DNA, including cccDNA, decreased over the 52-week study, regardless of therapy or serological outcome. Higher ratios of cccDNA to total HBV DNA were detected at week 52 than at baseline indicating a shift in predominance of nonreplicating virus in posttreatment specimens. In patients who achieved treatment-related or spontaneous hepatitis B e antigen (HBeAg) responses, including those harbouring tyrosine-methionine-aspartate-aspartate-mutant HBV, levels of intrahepatic and serum HBV DNA suppression were greater than those in patients without HBeAg responses. In conclusion, this pilot study of intrahepatic HBV replicative forms in patients with chronic hepatitis B indicated that total intrahepatic and, specifically, cccDNA levels are not static but change as a reflection of serological and virological events. © 2007 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd.en_HK
dc.relation.ispartofJournal of Viral Hepatitisen_HK
dc.rightsJournal of Viral Hepatitis. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAmino Acid Motifsen_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshBiopsy, Fine-Needleen_HK
dc.subject.meshDNA Probes - geneticsen_HK
dc.subject.meshDNA, Circular - analysis - geneticsen_HK
dc.subject.meshDNA, Viral - geneticsen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshHepatitis B e Antigens - blooden_HK
dc.subject.meshHepatitis B virus - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - pathology - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - therapeutic useen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMutationen_HK
dc.subject.meshPilot Projectsen_HK
dc.subject.meshVirus Replication - drug effectsen_HK
dc.titleQuantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1352-0504&volume=14&spage=55&epage=63&date=2007&atitle=Quantitative+analysis+of+HBV+cccDNA+from+clinical+specimens:+correlation+with+clinical+and+virological+response+during+antiviral+therapyen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2893.2006.00775.xen_HK
dc.identifier.pmid17212645-
dc.identifier.scopuseid_2-s2.0-33845722719en_HK
dc.identifier.hkuros126114en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33845722719&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue1en_HK
dc.identifier.spage55en_HK
dc.identifier.epage63en_HK
dc.identifier.isiWOS:000243008100008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridBourne, EJ=6701720023en_HK
dc.identifier.scopusauthoridDienstag, JL=24498972800en_HK
dc.identifier.scopusauthoridLopez, VA=7103022498en_HK
dc.identifier.scopusauthoridSander, TJ=7006529559en_HK
dc.identifier.scopusauthoridLonglet, JM=35074586800en_HK
dc.identifier.scopusauthoridHall, JG=7407379623en_HK
dc.identifier.scopusauthoridKwiatkowski, RW=7004485456en_HK
dc.identifier.scopusauthoridWright, T=7402187126en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridCondreay, LD=7004527800en_HK
dc.identifier.citeulike1010900-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats